ArticleBiomedical reports2020
Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease.
Article in Biomedical reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis.Frontiers in medicine · 2022Pooled it
- Serum Creatinine/Cystatin C-Based Muscle Indices for Sarcopenia and Graft Failure After Living Donor Liver Transplantation.Journal of clinical medicine · 2026Article
- Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease.Frontiers in medicine · 2025Article
- The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.Journal of cachexia, sarcopenia and muscle · 2025Article
- PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease.Biomedical reports · 2024Article
- What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?Life (Basel, Switzerland) · 2023Review
- Association between oral frailty and cystatin C-related indices-A questionnaire (OFI-8) study in general internal medicine practice.PloS one · 2023Article
- Sarcopenia in Chronic Liver Disease: A Metabolic Perspective.Journal of clinical and translational hepatology · 2022Review
- Serum creatinine to cystatin C ratio reflects preoperative and early postoperative walking ability in older patients with hip fracture.Journal of cachexia, sarcopenia and muscle · 2022Article
- Serum cystatin C is an early renal dysfunction biomarker in patients with hepatitis C virus.Egyptian liver journal · 2022Article
- A Novel Application of Serum Creatinine and Cystatin C to Predict Sarcopenia in Advanced CKD.Frontiers in nutrition · 2022Article
- Serum Creatinine to Cystatin C Ratio is an Effective Indicator for Muscle Strength Decline in Men with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2022Article
- Ratio of serum creatinine to cystatin C is related to leg strength in predialysis CKD patients.Clinical and experimental nephrology · 2021Observational
- Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease.Biomedical reports · 2021Article
- Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community- dwelling older adults with sarcopenia.Clinical and experimental nephrology · 2021Article
- Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus.Internal medicine (Tokyo, Japan) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum creatinine (Cr)-based glomerular filtration rate (CrGFR) is overestimated in liver disease. The present study evaluated whether the difference in CrGFR and cystatin C (CysC) GFR (dGFR) is significant in liver disease. The Cr-to-CysC ratio and sarcopenia index (SI) have been reported to correlate with muscle volume. An estimated total body muscle mass with Cr, CysC and calculated body muscle mass (CBMM) has also been reported to correlate with muscle mass. The applicability of dGFR, SI and CBMM for liver disease were evaluated. A total of 313 patients with liver damage were evaluated for Child-Pugh score, albumin-bilirubin (ALBI) score, model for end-stage liver disease, fibrosis-4, Cr, CysC, Cr-based estimated GFR (CreGFR), CysCGFR and grip strength. Of the 313 patients, 199 were evaluated using cross-sectional computed tomography (CT) of the third lumbar vertebra to determine the skeletal muscle (SM) mass. dGFR, CBMM and SI were compared to liver damage, muscle strength and muscle mass. In the 313 patients, dGFR was correlated with age, ALBI and grip strength; CBMM was correlated with body mass index (BMI) and grip strength; and SI was correlated with BMI and grip strength. In patients evaluated with CT, the correlation coefficients for CBMM and SI with SM were 0.804 and 0.293, respectively. Thus, CBMM and SI were associated with sarcopenia. The relationship between dGFR and ALBI does not differ with different grades of CrGFR-based chronic kidney disease (CKD). dGFR is a marker of liver damage and muscle strength regardless of CKD. CBMM and SI are markers for sarcopenia in liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.